<div id="readability-page-1"><p>In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Tonix Pharma, with a price target of <span id="expert-recommendation-target">$70.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, LeBoyer is an analyst with an average return of <span>-12.1%</span> and a 27.44% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Gyre Therapeutics, Ocugen, and Oncology Institute.</p> <p>In addition to Noble Financial, Tonix Pharma also received a Buy from Alliance Global Partners’s James Molloy in a report issued on December 3. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Tonix Pharma (NASDAQ: TNXP).</p></div>

TNXP

<p>Noble Financial's Robert LeBoyer reiterated a Buy rating for Tonix Pharma (TNXP) with a $70 price target. LeBoyer, who covers the Healthcare sector, has an average return of -12.1% and a 27.44% success rate. Alliance Global Partners also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on TNXP.</p>

Tonix Pharma (TNXP) Receives a Buy from Noble Financial